SCI Pharmtech, Inc. (TPE:4119)
Taiwan
· Delayed Price · Currency is TWD 48.20
+0.70 (1.47%)
Apr 29, 2026, 1:30 PM CST
SCI Pharmtech Revenue
In the year 2025, SCI Pharmtech had annual revenue of 1.34B TWD, down -11.81%. SCI Pharmtech had revenue of 355.47M in the quarter ending December 31, 2025, a decrease of -11.54%.
Revenue
1.34B
Revenue Growth
-11.81%
P/S Ratio
4.28
Revenue / Employee
5.62M
Employees
239
Market Cap
5.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.34B | -180.02M | -11.81% |
| Dec 31, 2024 | 1.52B | 319.58M | 26.54% |
| Dec 31, 2023 | 1.20B | 304.42M | 33.83% |
| Dec 31, 2022 | 899.74M | 35.52M | 4.11% |
| Dec 31, 2021 | 864.22M | -1.83B | -67.86% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LIWANLI Innovation | 243.15M |
| Orient Pharma | 1.40B |
| Formosa Laboratories | 4.85B |
| Easywell Biomedicals | 597.41M |
| Orient EuroPharma | 4.60B |
| Merdury Biopharmaceutical | 246.00K |
| Alar Pharmaceuticals | 2.75M |
| Allied Biotech | 849.51M |